{"classes":[{"categories":[{"measurements":[{"comment":"The median time to first new flare could not be estimated because \\<50% of patients had a new flare during the time period.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"The upper limit was not estimable in the study as it is longer than the duration of the study (24 weeks).","groupId":"OG001","lowerLimit":"94","upperLimit":"NA","value":"119"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"113"},{"groupId":"OG001","value":"115"}],"units":"Participants"}],"description":"Kaplan-Meier (KM) estimates of time to first new flare and confidence intervals were determined. Patients met definition of new flare if they had:\n\n* Flare in joint, not a previously affected joint (at baseline or during study)\n* Flare in joint previously affected (at baseline or during study) after previous flare in joint has resolved completely.\n\nPatients did not meet criterion of having new gout flare if:\n\n· Increasing/renewed gout pain in an affected joint before the flare has resolved completely.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients received 1 subcutaneous (sc) injection of canakinumab 150 mg and 1 intramuscular (im) injection of placebo to triamcinolone acetonide on Day 1. Patients could receive a re-dose of study drug on demand upon the occurrence of new flares, but re-dosing could not occur until 14 days had elapsed after the previous dose. Patients completing the 12 weeks core study were allowed to continue to be treated in another 12 weeks extension study for any new gout flare on demand with the same treatment as assigned in the core study.","id":"OG000","title":"Canakinumab 150 mg"},{"description":"Patients received 1 intramuscular (im) injection of triamcinolone acetonide 40 mg and 1 subcutaneous (sc) injection of placebo to canakinumab on Day 1. Patients could receive a re-dose of study drug on demand upon the occurrence of new flares, but re-dosing could not occur until 14 days had elapsed after the previous dose. Patients completing the 12 weeks core study were allowed to continue to be treated in another 12 weeks extension study for any new gout flare on demand with the same treatment as assigned in the core study.","id":"OG001","title":"Triamcinolone Acetonide 40 mg"}],"paramType":"MEDIAN","populationDescription":"The Full Analysis Set (FAS) consisted of all patients as randomized in the core study who had taken at least one dose of study drug.","reportingStatus":"POSTED","timeFrame":"24 weeks","title":"Time to First New Flare","type":"SECONDARY","unitOfMeasure":"Days"}